No Data
No Data
Increased support for innovative drugs, the collective rise of the innovative drug sector, sino biopharm (01177) rose 4.5%.
Jingu Finance News | The innovative drug sector as a whole is on the rise, with Lai Kai Medicine (02105) up 6.07%, Sino Biopharm (01177) up 4.5%, Genscript Bio (01548) up 4.07%, Hutchmed (China) (00013) up 2.68%, and Innovent Bio (01801) up 2.1%. The State Council Information Office held a series of themed press conferences on 'Promoting High-Quality Development', and Li Li, Director of the National Medical Products Administration, stated at the conference the increased support for pharmaceutical R&D innovation. This includes the evaluation and approval, inspection and verification of innovative drugs and medical instruments that are key to the country's support.
The biopharmaceutical sector is showing strong momentum. Kelunbotai Bio (06990) rose 6.6%, and institutions pointed out that innovative drug companies are gradually approaching the breakeven point in terms of profit and loss.
Jinwu Financial News | The biopharmaceutical sector has shown strong performance, with Kexingbo Tai Bio (06990) up 6.6%, Kanno (02162) up 5.9%, Hutchmed (China) (00013) up 4.42%, and Innovent Bio (01801) up 3.81%. In terms of news, Zhongyin International Securities stated that the revenue growth of the innovative drugs sector is strong. Among the sectors, the best-performing sector is innovative drugs (Biotech), with an average revenue growth of 25.3%, mainly due to the positive medical insurance payment environment for innovative drugs and the authorized revenue obtained by some innovative drug companies through product overseas licensing.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
HK Stocks | hutchmed (china) (00013) fell more than 4% recently as the company withdrew the joint application for Fruquintinib and Paclitaxel.
Hutchmed (china) (00013) is currently down more than 4%, as of the time of writing, down 4.3% to HKD 26.7, with a turnover of HKD 74.0802 million.
Express News | - HUTCHMED China Ltd - Clinical Data to Be Presented at Esmo and Wclc
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
No Data
No Data